Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Christopher Russell

Urology Orlando, FL Medical Doctor

NPI 1578942918 CMS profile 2787025

1812 N Mills Ave, Orlando, FL 32803

Open in the dashboard

General payments

$83,893

127 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Russell of Orlando, FL is reported in the CMS Open Payments database as having received $83,893 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59,727 59
2024 General $9,891 34
2023 General $13,657 20
2022 General $344 10
2021 General $246 3
2020 General $27 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Russell
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Christopher Russell were reported at $59,727. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Christopher Russell Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $27 $246 $87–$645 $114
2021 $246 $358 $111–$1,000 $132
2022 $344 $476 $143–$1,263 $149
2023 $13,657 $560 $168–$1,461 $160
2024 $9,891 $563 $170–$1,464 $164
2025 $59,727 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Intuitive Surgical, Inc. $82,761 101 payments
  2. Boston Scientific Corporation $331 7 payments
  3. Coloplast Corp $171 4 payments
  4. AngioDynamics, Inc. $148 1 payment
  5. Teleflex LLC $145 2 payments
  6. Astellas Pharma US Inc $140 4 payments
  7. Urogen Pharma, Inc. $68 4 payments
  8. KARL STORZ Endoscopy-America $68 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $27 1 payment
  10. Endo Pharmaceuticals Inc. $22 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,650 15 payments
  2. Education $31,044 16 payments
  3. Travel and Lodging $8,529 27 payments
  4. Food and Beverage $5,232 66 payments
  5. Consulting Fee $3,429 2 payments
  6. Gift $9 1 payment
Products named General payments · program years 2020–2025
  1. Da Vinci Surgical System $79,261 98 payments
  2. DA VINCI SP $3,500 3 payments
  3. NANOKNIFE $148 1 payment
  4. UroLift System $130 1 payment
  5. LithoVue $114 3 payments
  6. Luja Coude $110 1 payment
  7. General - Kidney Stone Disease $106 1 payment
  8. JELMYTO $68 4 payments
  9. n.a. $68 1 payment
  10. SpeediCath $61 3 payments
  11. Other $270 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,059

Median for Urology: 1,053

Drug cost

$26,269

Median for Urology: $101,464

Branded share of claims

24.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 18 $11,027
Tamsulosin Hcl Generic 366 $4,058
Solifenacin Succinate Generic 79 $3,937
Finasteride Generic 106 $1,295
Trospium Chloride Generic 32 $1,265
Silodosin Generic 13 $1,061
Testosterone Cypionate Generic 18 $1,015
Testosterone Generic 13 $1,007
Ciprofloxacin Hcl Generic 88 $424
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 165 $406

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$178,881

Of which drugs: $3,830

Medicare patients

361

Average age 73

Services billed

2,020

114 women, 247 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 47%
Arthritis 47%
Ischemic heart disease 45%
Cancer 43%
Diabetes 35%
Atrial fibrillation 24%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 20 42 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record